clenoliximab

a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for CD4 molecule on the surface of T lymphocytes for treatment of rheumatoid arthritis.

Also Known As:

IDEC-151; SB-217969

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        clenoliximab: 2
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        clenoliximab: 2
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        clenoliximab: 2

Experts

1.	Griswold, D E: 1 article (02/2000)
2.	Podolin, P L: 1 article (02/2000)
3.	Reddy, M: 1 article (02/2000)
4.	Truneh, A: 1 article (02/2000)
5.	Webb, E F: 1 article (02/2000)

Related Diseases

1.	Contact Dermatitis (Eczema, Contact) 02/01/2000 - "Administration of a single 2-mg dose of either clenoliximab or keliximab to HuCD4/Tg mice prior to sensitization significantly reduced post-challenge tissue swelling, and levels of IFN-gamma and IL-4, indicating that CD4+ T-cell depletion is not required for anti-CD4 mAb-mediated inhibition of contact sensitivity. "
2.	Rheumatoid Arthritis 09/01/1999 - "A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis."

Related Drugs and Biologics

1.	Interleukin-4 (Interleukin 4)
2.	keliximab